Josephine M I Vos
Overview
Explore the profile of Josephine M I Vos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sonneveld M, Bernelot Moens S, van den Akker J, Vos J, Kwakernaak A
EJHaem
. 2024 Dec;
5(6):1322-1324.
PMID: 39691267
Background: Transfusion reactions occur at an estimated incidence of 2 per 1.000 transfused products. Anaphylactic transfusion reactions are rarer, and seen in 1 per 10.000 transfusions, and are mostly related...
2.
Durot E, Kanagaratnam L, Zanwar S, Kaufman A, DSa S, Toussaint E, et al.
Am J Hematol
. 2024 Nov;
100(2):338-341.
PMID: 39588555
No abstract available.
3.
Petersen R, Fijen L, Franssen L, Vos J, Cohn D
J Allergy Clin Immunol Glob
. 2024 Sep;
3(4):100322.
PMID: 39282617
Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.
4.
Roth A, Berentsen S, Barcellini W, DSa S, Jilma B, Michel M, et al.
EClinicalMedicine
. 2024 Aug;
74:102733.
PMID: 39091672
Background: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia mediated by the classical complement pathway (CP). Sutimlimab selectively targets complement C1s inhibiting classical CP activation. In CADENZA Part...
5.
Berentsen S, Vos J, Malecka A, Tjonnfjord G, DSa S
Expert Rev Hematol
. 2024 Jun;
17(8):479-492.
PMID: 38938203
Introduction: During the last decades, the pathogenesis of cold agglutinin disease (CAD) has been well elucidated and shown to be complex. Several documented or investigational therapies have been made available....
6.
Jalink M, Jacobs C, Khwaja J, Evers D, Bruggeman C, Fattizzo B, et al.
Blood Adv
. 2024 Mar;
8(11):2622-2634.
PMID: 38507742
Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial...
7.
Verbinnen M, Sprangers B, Abrahams A, Koshy P, van Kruijsdijk R, Philipse E, et al.
Nephrol Dial Transplant
. 2024 Jan;
39(5):888-892.
PMID: 38192041
No abstract available.
8.
DSa S, Vos J, Barcellini W, Wardecki M, Perrin L, Barker G, et al.
Blood
. 2023 Dec;
143(8):713-720.
PMID: 38085846
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by complement pathway-mediated hemolysis. Riliprubart (SAR445088, BIVV020), a second-generation classical complement inhibitor, is a humanized monoclonal antibody that selectively inhibits...
9.
Houben E, de Groot P, Vegting Y, Vos J, Nur E, Hilhorst M, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834788
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare heterogeneous disease in which treatment must be initiated early to prevent irreversible organ damage and death. There are several diseases that...
10.
Mulder F, Evers D, de Haas M, Cruijsen M, Bernelot Moens S, Barcellini W, et al.
Front Immunol
. 2023 Oct;
14:1228142.
PMID: 37795092
Autoimmune hemolytic anemia (AIHA) is an acquired hemolytic disorder, mediated by auto-antibodies, and has a variable clinical course ranging from fully compensated low grade hemolysis to severe life-threatening cases. The...